BR112015021162A2 - peptídeo tendo 5 epítopos de ctl ligados - Google Patents

peptídeo tendo 5 epítopos de ctl ligados

Info

Publication number
BR112015021162A2
BR112015021162A2 BR112015021162A BR112015021162A BR112015021162A2 BR 112015021162 A2 BR112015021162 A2 BR 112015021162A2 BR 112015021162 A BR112015021162 A BR 112015021162A BR 112015021162 A BR112015021162 A BR 112015021162A BR 112015021162 A2 BR112015021162 A2 BR 112015021162A2
Authority
BR
Brazil
Prior art keywords
peptide
linked
ctl
cancer
epitopes
Prior art date
Application number
BR112015021162A
Other languages
English (en)
Inventor
Wada Hiroshi
Fukaya Satoshi
Utsugi Teruhiro
Osada Toshihiro
Original Assignee
Taiho Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taiho Pharmaceutical Co Ltd filed Critical Taiho Pharmaceutical Co Ltd
Publication of BR112015021162A2 publication Critical patent/BR112015021162A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

resumo patente de invenção: "peptídeo tendo 5 epítopos de ctl ligados". a presente invenção refere-se a um peptídeo de antígeno de câncer que não requer inspeção de tipo de hla, que não é restrito a pacientes tendo um tipo de hla específico e que pode ser administrado a uma ampla faixa de pacientes com câncer como uma vacina de peptídeo para câncer. um peptídeo tendo 5 epítopos de ctl ligados, o peptídeo sendo obtido através de ligação, através de um ligante, de 5 peptídeos de epítopo de ctl selecionados de um grupo de peptídeos de epítopo de ctl relatados ser capazes de indução de ctl e derivados das moléculas de antígeno de tumor.
BR112015021162A 2013-03-08 2014-03-05 peptídeo tendo 5 epítopos de ctl ligados BR112015021162A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2013047271 2013-03-08
PCT/JP2014/055555 WO2014136814A1 (ja) 2013-03-08 2014-03-05 新規ｃｔｌエピトープ５連結ペプチド

Publications (1)

Publication Number Publication Date
BR112015021162A2 true BR112015021162A2 (pt) 2017-10-10

Family

ID=51491326

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015021162A BR112015021162A2 (pt) 2013-03-08 2014-03-05 peptídeo tendo 5 epítopos de ctl ligados

Country Status (13)

Country Link
US (1) US9701729B2 (pt)
EP (1) EP2966092A4 (pt)
JP (1) JP6077641B2 (pt)
KR (1) KR101851666B1 (pt)
CN (1) CN105008399B (pt)
AU (1) AU2014227019B2 (pt)
BR (1) BR112015021162A2 (pt)
CA (1) CA2901984A1 (pt)
HK (1) HK1215440A1 (pt)
MX (1) MX2015011257A (pt)
RU (1) RU2627175C2 (pt)
TW (1) TW201438731A (pt)
WO (1) WO2014136814A1 (pt)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3061771B1 (en) * 2013-10-21 2020-04-15 Taiho Pharmaceutical Co., Ltd. Novel four-ctl epitope-joined peptide
JP7314441B2 (ja) * 2018-01-22 2023-07-26 国立感染症研究所長 選択的ｃｄ８陽性ｔ細胞誘導ワクチン抗原
AU2020411439A1 (en) * 2019-12-26 2022-08-04 Taiho Pharmaceutical Co., Ltd. Agent for adjuvant therapy

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080286228A1 (en) 1995-10-20 2008-11-20 Tarantolo Stefano R Compositions and methods for enhancing immune responses mediated by antigen-presenting cells
ATE406913T1 (de) * 1996-03-10 2008-09-15 Meiji Dairies Corp Auf peptiden basierendes immunotherapeutisches mittel gegen allergien
JP4138073B2 (ja) 1998-05-08 2008-08-20 株式会社グリーンペプタイド ヒト癌退縮抗原タンパク質
WO2000012701A1 (fr) 1998-08-28 2000-03-09 Sumitomo Pharmaceuticals Company, Limited Nouvelle proteine d'antigene tumoral sart-3 et peptide d'antigene tumoral de celle-ci
US6667037B1 (en) * 1998-10-09 2003-12-23 Ludwig Institute For Cancer Research Isolated peptides which bind to HLA-B35 molecules, larger peptides which contain these, nucleic acid molecules encoding peptides, and uses thereof
US6660843B1 (en) 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
JP4658423B2 (ja) * 1999-08-03 2011-03-23 ザ オハイオ ステイト ユニバーシティ Ｈｅｒ−２タンパク質に対する免疫反応性を増強するためのポリペプチドおよびポリヌクレオチド
WO2001011044A1 (en) 1999-08-05 2001-02-15 Kyogo Itoh Tumor antigen
KR20020047249A (ko) 1999-10-19 2002-06-21 에드워드 에이. 맥더모트, 주니어 Ｍａｇｅ-ａ12 항원성 펩티드 및 그의 용도
CA2393730A1 (en) * 1999-12-13 2001-06-14 Epimmune Inc. Hla class i a2 tumor associated antigen peptides and vaccine compositions
JP2002008491A (ja) * 2000-06-27 2002-01-11 Matsushita Electric Works Ltd スイッチ装置
ES2304398T3 (es) 2000-07-31 2008-10-16 Green Peptide Co., Ltd. Antigeno de tumores.
JP4097178B2 (ja) 2000-10-03 2008-06-11 株式会社グリーンペプタイド 腫瘍抗原
ATE441713T1 (de) 2002-09-27 2009-09-15 Dainippon Sumitomo Pharma Co Tumorantigenprotein und dessen verwendung
AU2003280688A1 (en) * 2003-10-31 2005-05-19 Kurume University Combination therapy of peptide vaccination and estramustine treatment
JP4547197B2 (ja) 2004-06-30 2010-09-22 公正 安元 癌特異的腫瘍抗原
ES2352855T3 (es) * 2005-11-30 2011-02-23 International Institute Of Cancer Immunology, Inc. Nuevos compuestos peptídicos del tumor de wilms.
RU2008136201A (ru) 2006-02-09 2010-03-20 Дзе Юниверсити Оф Мельбурн (Au) Фторидная композиция и способы минерализации зубов
JP5114403B2 (ja) 2006-07-11 2013-01-09 株式会社グリーンペプタイド Ｈｌａ−ａ３スーパータイプアレル陽性前立腺癌患者に対する癌ワクチン療法に有用なｓａｒｔ３由来ペプチド
GB0717864D0 (en) 2007-09-13 2007-10-24 Peptcell Ltd Peptide sequences and compositions
KR101294514B1 (ko) 2007-09-18 2013-08-12 가부시키가이샤 그린 펩티드 Ｃｔｌ 유도제 조성물
CA2804127A1 (en) 2010-07-07 2012-01-12 Green Peptide Co., Ltd. Cancer peptide vaccine

Also Published As

Publication number Publication date
CN105008399B (zh) 2018-09-28
JPWO2014136814A1 (ja) 2017-02-16
KR101851666B1 (ko) 2018-04-24
RU2015142659A (ru) 2017-04-13
CA2901984A1 (en) 2014-09-12
RU2627175C2 (ru) 2017-08-03
EP2966092A4 (en) 2016-11-16
MX2015011257A (es) 2015-11-16
US20160017014A1 (en) 2016-01-21
KR20150125652A (ko) 2015-11-09
AU2014227019A1 (en) 2015-09-03
WO2014136814A1 (ja) 2014-09-12
AU2014227019B2 (en) 2016-10-27
TW201438731A (zh) 2014-10-16
JP6077641B2 (ja) 2017-02-08
EP2966092A1 (en) 2016-01-13
HK1215440A1 (zh) 2016-08-26
US9701729B2 (en) 2017-07-11
TWI561243B (pt) 2016-12-11
CN105008399A (zh) 2015-10-28

Similar Documents

Publication Publication Date Title
CL2021000088A1 (es) Anticuerpos anti-cd27 (divisional de solicitud 779-2019).
BR112016015140A2 (pt) imunoglobulina com fabs in-tandem e usos das mesmas
CL2017001364A1 (es) Nuevos indazoles sustituidos, procedimientos para su preparación, preparaciones farmacéuticas que los contienen, así como su uso para la preparación de medicamentos.
BR112013022397A2 (pt) vacinas combinadas com doses menores de antígeno e/ou adjuvante
BR112016022785B8 (pt) composto inibidor de triptofano-2,3-dioxigenase (tdo) e/ou indoleamina-2,3-dioxigenase (ido), composição farmacêutica, e, uso de composto inibidor de triptofano-2,3-dioxigenase (tdo) e/ou indoleamina-2,3dioxigenase (ido) ou de um sal farmaceuticamente aceitável do mesmo para fabricação de um medicamento
EA201690495A1 (ru) Меченые ингибиторы простатического специфического мембранного антигена (псма), их применение в качестве агентов для визуализации и фармацевтических агентов для лечения рака предстательной железы
GT201300306A (es) Anticuerpos anti-angptl3 y usos de los mismos
BR112014018561A8 (pt) Anticorpo; ácido nucleico; célula hospedeira; composição farmacêutica; uso de um anticorpo; método para produção de um anticorpo; e método para produção de uma linhagem celular que produz um anticorpo
BR112019008351A2 (pt) imunoglobulinas e usos das mesmas
BR112015004875A2 (pt) formulações de anticorpo e seus usos
CL2012003458A1 (es) Vector que comprende un polipeptido antigénico de campylobacter; composicion farmacéutica que comprende dicho vector; uso del vector para mejorar respuesta inmune del sujeto al polipéptido antigénico.
BR112015018335A2 (pt) Composições nutritivas contendo um componente peptídico com propriedades anti-inflamatórias e usos das mesmas
BR112012021326B8 (pt) anticorpo monoclonal anti-vegf completamente humano, método de preparação e uso do mesmo
CL2020001542A1 (es) Ligandos de psma para la formación de imágenes y endorradioterapia.
CL2020001334A1 (es) Anticuerpos que se unen a la proteína de envoltura del virus zika y usos de los mismos. (divisional solicitud 201900999)
BR112017008952A2 (pt) métodos e composições para vírus recombinantes da dengue para desenvolvimento de vacina e diagnóstico
BR112014018964A8 (pt) Anticorpo anti-vegf e uso de um anticorpo anti-vegf
PH12016500742A1 (en) Novel peptide having 4 linked ctl epitopes
BR112015020199A2 (pt) usos terapêuticos para anticorpos de vegfr1
BR112015021162A2 (pt) peptídeo tendo 5 epítopos de ctl ligados
BR112015032388A2 (pt) métodos e composições para as vacinas contra o vírus da dengue
BR112015021265A2 (pt) métodos de aperfeiçoamento de uso para secretoglobinas humanas recombinantes
MX2021010021A (es) Proteínas sintéticas autoensamblables.
BR112015017909A2 (pt) redução do risco de doença autoimune
BR112014030288A8 (pt) composição farmacêutica, uso da mesma, e, uso de metanossulfonilacetonitrila

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A ANUIDADE.

B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements